The latest from small and Emerging Pharma companies featuring Isomorphic Labs and Anagram Therapeutics. 

For news on the large and mid-sized bio/pharmaceutical companies, see Global Briefs. 

* Isomorphic Labs Raises $2.1 Bn for AI Drug Design Engine 
* Blackstone Investing $250 M in Anagram Therapeutics for Pancretic Enzyme Replacement Therapy

---

Isomorphic Labs Raises $2.1 Bn for AI Drug Design Engine 
Isomorphic Labs, an AI drug design and development company, has announced it has raised $2.1 billion in Series B funding. The new capital will be used for the continued development and deployment of Isomorphic Labs’ AI drug design engine (IsoDDE), to accelerate and expand its pipeline of therapeutic programs towards the clinic.  

Source: Isomorphic Labs 

---

Blackstone Investing $250 M in Anagram Therapeutics for Pancretic Enzyme Replacement Therapy 
Blackstone Life Sciences has announced a $250-million investment in Anagram Therapeutics, a clinical-stage private bio/pharmaceutical company focused on cystic fibrosis, pancreatic cancer, and related disorders. The investment will help fund the further development, approval, and launch of Anagram’s ANG003, an orally delivered recombinant enzyme replacement therapy that has demonstrated positive clinical data in people with exocrine pancreatic insufficiency due to cystic fibrosis.

Source: Blackstone Life Sciences